Structured evidence table for Saffron Mild Depression Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Saffron Mild Depression Randomized Trial | This literature review synthesises evidence from randomised controlled trials, meta-analyses, safety data, dosing patterns, proposed mechanisms, and guideline positioning regarding saffron in depression, with a focus on adult major depressive disorder and related depressive symptomatology. | 4 | Dimech L (2026) | The Role of Saffron in the Treatment of Depression: A Literature Review. |
| Saffron Mild Depression Randomized Trial | Across placebo-controlled trials in mild-to-moderate depression, saffron, most commonly administered at 30 mg per day for approximately six weeks, has been associated with clinically meaningful reductions in depressive symptom severity, typically measured using the Hamilton Depression Rating Scale (HAM-D). | 4 | Dimech L (2026) | The Role of Saffron in the Treatment of Depression: A Literature Review. |
| Saffron Mild Depression Randomized Trial | Meta-analytic evidence generally indicates superiority over placebo and similar efficacy to selective serotonin reuptake inhibitors (SSRIs), with an overall favourable short-term tolerability profile; however, confidence is constrained by small sample sizes, restricted settings, variable product standardisation (including stigma versus petal preparations), and risk of bias/publication bias. | 4 | Dimech L (2026) | The Role of Saffron in the Treatment of Depression: A Literature Review. |
| Saffron Mild Depression Randomized Trial | Saffron ( Crocus sativus L.) has attracted increasing interest as a nutraceutical option for depressive disorders, particularly for patients who experience incomplete response or poor tolerability with conventional treatments. | 4 | Dimech L (2026) | The Role of Saffron in the Treatment of Depression: A Literature Review. |
| Saffron Mild Depression Randomized Trial | However, evidence of saffron activity on reduced hedonic responsiveness and motivational anhedonia is limited. | 4 | Corridori E (2025) | Therapeutic Potential of Saffron Extract in Mild Depression: A Study of Its Role on Anhedonia in Rats and Humans. |
| Saffron Mild Depression Randomized Trial | In parallel, with a pilot double-blind placebo-controlled study we investigated whether saffron add-on therapy reduced symptoms of depression and anhedonia, measured by the Montgomery-Åsberg Depression Rating Scale. | 4 | Corridori E (2025) | Therapeutic Potential of Saffron Extract in Mild Depression: A Study of Its Role on Anhedonia in Rats and Humans. |
| Saffron Mild Depression Randomized Trial | Repeated saffron administration restored motivation and reactivity to reward-associated cues in anhedonic rats, likely modulating dopaminergic transmission and BDNF-TrkB signaling. | 4 | Corridori E (2025) | Therapeutic Potential of Saffron Extract in Mild Depression: A Study of Its Role on Anhedonia in Rats and Humans. |
| Saffron Mild Depression Randomized Trial | Drugs generally used in major depressive disorder are considered inappropriate for the more common milder forms. | 4 | Corridori E (2025) | Therapeutic Potential of Saffron Extract in Mild Depression: A Study of Its Role on Anhedonia in Rats and Humans. |
Source documents